The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Human equilibrative nucleoside transporter 1 as a predictor of efficacy to gemcitabine in angiosarcoma and leiomyosarcoma.
 
Bruno Vincenzi
No Relationships to Disclose
 
Silvia Stacchiotti
No Relationships to Disclose
 
Paola Collini
No Relationships to Disclose
 
Francesco Pantano
No Relationships to Disclose
 
Giuseppe Perrone
No Relationships to Disclose
 
Michele Iuliani
No Relationships to Disclose
 
Alfonso Baldi
No Relationships to Disclose
 
Giuseppe Badalamenti
No Relationships to Disclose
 
Roberta Sanfilippo
No Relationships to Disclose
 
Daniele Santini
No Relationships to Disclose
 
Andrea Onetti-Muda
No Relationships to Disclose
 
Alessandro Gronchi
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Amgen; Bayer; Lilly; Novartis; Pfizer
Travel, Accommodations, Expenses - PharmaMar
 
Paolo Giovanni Casali
Honoraria - Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Amgen/Dompé; ARIAD/Merck; Bayer; Blueprint Medicines; GlaxoSmithKline; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; PharmaMar
Research Funding - Amgen/Dompé (Inst); Bayer (Inst); Eisai (Inst); GlaxoSmithKline (Inst); MolMed (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Novartis; PharmaMar
 
Angelo Paolo Dei Tos
No Relationships to Disclose
 
Giuseppe Tonini
No Relationships to Disclose